Abstract:T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity. Numerous strategies are being developed to overcome these barriers, which include improving culture conditions and manufacturing protocols, implementing novel CAR designs, and novel approaches to engineering the T cell phenotype. In this review, we describe the various emerging strategies to improve CAR T cell therapy for solid tumours. We specifically focus on new strategies to modulate cell function and fate that have precipitated from the growing knowledge of transcriptional circuits driving T cell differentiation, with the ultimate goal of driving more productive anti-tumour T cell immunity. Evidence shows that enrichment of particular phenotypic subsets of T cells in the initial cell product correlates to improved therapeutic responses and clinical outcomes. Furthermore, T cell exhaustion and poor persistence are major factors limiting therapeutic efficacy. The latest preclinical work shows that targeting specific master regulators and transcription factors can overcome these key barriers, resulting in superior T cell therapeutic products. This can be achieved by targeting key transcriptional circuits promoting memory-like phenotypes or sustaining key effector functions within the hostile tumour microenvironment. Additional discussion points include emerging considerations for the field such as (i) targeting permutations of transcription factors, (ii) transient expression systems, (iii) tissue specificity, and (iv) expanding this strategy beyond CAR-T cell therapy and cancer.

Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Optimizing the manufacturing and antitumour response of CAR T therapy

Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics

Tuning CAR T-cell therapies for efficacy and reduced toxicity

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

Prospects and challenges for use of CAR T cell therapies in solid tumors

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Cutting-Edge CAR Engineering: Beyond T Cells

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Tuning the performance of CAR T cell immunotherapies

CAR-T cell therapy: current limitations and potential strategies

Transcription factors in chimeric antigen receptor T-cell development

A long way to the battlefront: CAR T cell therapy against solid cancers.